| 1 Leaving the study early |
3 |
353 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.40 [0.29, 0.54] |
| 2 Global state: not improved after 8 years (Psychiatric rating scale, not improved=1,2; improved=4,5) |
1 |
40 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.53, 1.11] |
| 3 Rehospitalisation within 3 years ‐ completer |
1 |
80 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.29 [1.31, 4.03] |
| 4 Rehospitalisation within 3 years ‐ intent to treat |
1 |
127 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.30 [1.50, 3.54] |
| 5 Adverse effects: various outcomes |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 5.1 drowsiness |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
5.65 [2.72, 11.73] |
| 5.2 restlessness |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.19 [0.83, 1.71] |
| 5.3 constipation |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.71 [1.37, 5.35] |
| 5.4 nausea or upper gastrointestinal distress |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
6.17 [1.92, 19.79] |
| 5.5 dryness of mouth or throat |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.63 [1.67, 12.82] |
| 5.6 dizziness, faintness or weakness |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.41 [1.59, 12.29] |
| 5.7 muscle rigidity |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.54 [0.60, 3.97] |
| 5.8 nasal congestion |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.10 [0.69, 6.43] |
| 5.9 facial rigidity |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.31 [0.77, 6.96] |
| 5.10 tremor of hands, arms or face |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.05 [0.29, 3.77] |
| 5.11 headache |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.84 [0.33, 2.13] |
| 5.12 loss of associated movements |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.26 [0.22, 7.35] |
| 5.13 akathesis‐restlessness of feet |
1 |
162 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.40 [0.35, 5.67] |
